It is well established that the tumor microenvironment is

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2
853
Quote:
It is well established that the tumor microenvironment is essential to the pathogenesis of ALL (Acute Lymphoblastic Leukemia). For example, various cytokines, chemokines, and adhesion molecules within the LymphNodes, spleen, and BoneMarrow microenvironment, as well as signaling by the B-cell antigen receptor (BCR), mediate ALL cell localization, growth, survival, and drug resistance. Chemokines and their receptors are key regulators of immune activity, and thus, disruption of their normal functions may promote malignancy. Chemoattractant cytokines are a large family of tumor and stromal cell-secreted cytokines whose main function is to mediate cancer cell directional migration and invasion abilities. Most cancers overexpress both chemokines and chemokine receptors because of the activity of deregulated transcription factors and/or cancer-promoting genes. For example, CCL5 and its cognate receptor CCR5 are thought to be critical to cancer progression in this context, and similarly, CXCL12 and CCR5 have been reported to be essential to multiple phases of tumorigenesis, including tumor cell proliferation, survival, invasion, and metastasis, as well as angiogenesis.


Quote:
...Moreover, CCR5 may promote tumor cell survival via both post-translational inactivation of the cell death machinery, and increased transcription of cell survival-related genes. Thus, extensive previous research promotes CCR5 as a promising therapeutic target for anti-cancer drug development. The CCR5 inhibitor maraviroc has recently been shown to exert anti-cancer activity in colon, breast, and gastric cancer.


taken from here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411794/

I think we are all aware LRM exceeds maraviroc in every respect in its capacity to bind to CCR5, and we've already shown our effectiveness in mTNBC. Dostarlimab, a tremendously good PD-1 inhibitor by GSK has shown its effectiveness in treating Colon Cancer, but not metastasis, where LRM executes and excels. Along these lines, PD-1 blockade has been shown to be tremendously effective in treating Long Haulers as has LRM. Dostarlimab and Leronlimab could knock it out of the park. Long Haulers can take years to resolve it seems and so far there are no treatments.

As Kelly has stated multiple times, We will be an Oncology Company. HIV is our pathway there. Why? because, cancer proliferates in AIDS. How are we preventing AIDS and the spread of HIV? By the blockade of CCR5, LRM acts as a viral entry inhibitor. How is it that by blocking CCR5, cancer is also prevented from metastasizing, through loss of the CCR5 cytokine signaling pathway? But how is it that with the complete elimination of CCR5, leukemia and lymphoma are eradicated? CCR5 is a key to cancer genesis, tumorigenesis, metastasis and proliferation. Something is behind CCR5 and cancer and LRM will be the key that unlocks the door.

Pitt has brought to light that the inventor of maraviroc is aware of this CCR5 blockers role in oncology. He is also aware of a superior CCR5 blockade in the same environment. He will vie to obtain the drug by one means or another.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading